Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Crestline Management LP

Crestline Management LP lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 259.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,789 shares of the biopharmaceutical company's stock after acquiring an additional 2,013 shares during the period. Crestline Management LP's holdings in Regeneron Pharmaceuticals were worth $1,987,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Cutter Capital Management LP grew its holdings in shares of Regeneron Pharmaceuticals by 117.6% during the fourth quarter. Cutter Capital Management LP now owns 31,500 shares of the biopharmaceutical company's stock worth $22,438,000 after buying an additional 17,024 shares in the last quarter. Capitolis Liquid Global Markets LLC boosted its position in Regeneron Pharmaceuticals by 128.9% during the fourth quarter. Capitolis Liquid Global Markets LLC now owns 87,000 shares of the biopharmaceutical company's stock worth $61,973,000 after acquiring an additional 49,000 shares during the last quarter. Cetera Investment Advisers grew its stake in Regeneron Pharmaceuticals by 5.6% during the 4th quarter. Cetera Investment Advisers now owns 9,239 shares of the biopharmaceutical company's stock valued at $6,581,000 after acquiring an additional 494 shares in the last quarter. BOKF NA raised its holdings in Regeneron Pharmaceuticals by 83.6% in the 4th quarter. BOKF NA now owns 3,203 shares of the biopharmaceutical company's stock valued at $2,232,000 after acquiring an additional 1,458 shares during the last quarter. Finally, Brevan Howard Capital Management LP boosted its holdings in shares of Regeneron Pharmaceuticals by 141.5% during the 4th quarter. Brevan Howard Capital Management LP now owns 7,690 shares of the biopharmaceutical company's stock worth $5,478,000 after purchasing an additional 4,506 shares during the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

REGN has been the subject of several recent research reports. Robert W. Baird cut their price target on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a report on Friday, April 25th. UBS Group reduced their price target on Regeneron Pharmaceuticals from $768.00 to $633.00 and set a "neutral" rating on the stock in a report on Wednesday, April 30th. Royal Bank of Canada dropped their price objective on shares of Regeneron Pharmaceuticals from $1,051.00 to $943.00 and set an "outperform" rating for the company in a report on Wednesday, April 30th. Bank of America reduced their target price on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating on the stock in a research note on Thursday, April 17th. Finally, Leerink Partnrs raised shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, February 5th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, eighteen have issued a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $892.60.

Regeneron Pharmaceuticals Stock Down 3.6 %

Shares of NASDAQ:REGN traded down $19.89 during trading on Friday, hitting $527.78. The company's stock had a trading volume of 1,498,740 shares, compared to its average volume of 769,971. The business has a 50 day moving average price of $613.08 and a two-hundred day moving average price of $695.07. The company has a market capitalization of $57.70 billion, a PE ratio of 13.79, a P/E/G ratio of 2.34 and a beta of 0.43. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $520.50 and a fifty-two week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). The company had revenue of $3.03 billion for the quarter, compared to analysts' expectations of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. Regeneron Pharmaceuticals's revenue for the quarter was down 3.7% compared to the same quarter last year. During the same quarter last year, the company earned $9.55 EPS. As a group, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.67%. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.96%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.